1.988EUR+0.81%Mkt Cap: —P/E: —1d ago
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activiti…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value76.04M $
Revenue (TTM)4.42M $
Gross Profit580.43K $
Net Income (TTM)-6.03M $
Revenue/Share0.1261 USD
Last Price1.988 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees49
CountryGB
SectorHealthcare
Industry—
ISINFR0012616852
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-12.90
EV/Revenue17.22
P/S—
P/B15.42
EPS (TTM)-0.15
EPS (Forward)—
52W Range
1.95448% of range2.025
52W High2.025 EUR
52W Low1.954 EUR
Profitability
Gross Margin13.14%
Oper. Margin-165.02%
EBITDA Margin-133.47%
Profit Margin-136.60%
ROE-92.29%
ROA-25.97%
Growth
Revenue Growth-11.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.19M $
CapEx (TTM)—
FCF Margin-7.07%
FCF Yield—
Net Debt308.70K $
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity84.33
Current Ratio1.06
Quick Ratio0.99
Book Value/Sh0.1280 EUR
Cash/Share0.1000 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.18.22M
Float19.75M
Insiders29.97%
Institutions3.74%
Technical
SMA 501.254 (+58.5%)
SMA 2001.387 (+43.4%)
Beta0.45
S&P 52W Chg20.80%
Avg Vol (30d)421
Avg Vol (10d)861
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—